Vaxcyte, Inc. PCVX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $262.31M+49.5% | $175.43M-37.9% | $282.55M-8.3% | $308.06M-11.5% | $348.17M-10.5% | ||
| $1.48B+6.4% | $1.39B-3.0% | $1.43B+5.6% | $1.35B+2.2% | $1.32B-2.5% | ||
| $1.81B+11.4% | $1.63B-7.9% | $1.77B+3.0% | $1.72B0.0% | $1.72B-4.0% | ||
| $260.7M+1.3% | $257.37M+1.5% | $253.49M+4.6% | $242.27M+11.6% | $217.16M+9.6% | ||
| $1.53B+11.6% | $1.38B-2.1% | $1.4B-11.6% | $1.59B-4.3% | $1.66B-3.6% | ||
| $3.35B+11.5% | $3B-5.3% | $3.17B-4.0% | $3.31B-2.2% | $3.38B-3.8% | ||
| $214.34M+24.8% | $171.79M+15.0% | $149.34M+25.9% | $118.6M+21.5% | $97.65M-1.2% | ||
| $242.08M+17.7% | $205.75M+2.9% | $200.05M+29.5% | $154.49M+59.3% | $97M-30.8% | ||
| $352.29M+11.1% | $317.21M+13.8% | $278.72M+19.1% | $234.03M+31.4% | $178.08M-13.3% | ||
| 500M0.0% | 500M0.0% | 500M0.0% | 500M0.0% | 500M+390,525% | ||
| -$2.48B-14.9% | -$2.15B-12.9% | -$1.91B-12.6% | -$1.7B-10.9% | -$1.53B-10.1% | ||
| $3B+11.6% | $2.69B-7.2% | $2.89B-5.8% | $3.07B-4.0% | $3.2B-3.2% | ||
| $3.35B+11.5% | $3B-5.3% | $3.17B-4.0% | $3.31B-2.2% | $3.38B-3.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vaxcyte, Inc.'s total assets?
- Vaxcyte, Inc. (PCVX) holds $3.3B in total assets, down 0.9% year over year.
- How much debt does Vaxcyte, Inc. have?
- Vaxcyte, Inc. carries $116.3M in total debt against $3.0B of shareholders' equity, a debt-to-equity ratio of 0.04.
- How much cash does Vaxcyte, Inc. have?
- Vaxcyte, Inc. holds $262.3M in cash and equivalents.
- Can Vaxcyte, Inc. cover its short-term obligations?
- Its current ratio is 7.49 — current assets exceed current liabilities.
- Where does Vaxcyte, Inc.'s balance sheet data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.